Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABX-101 for Moderate-to-Severe Traumatic Brain Injury
NCT06096415Phase 2Not yet recruiting
- Sponsor
- Abalonex, LLC
- Start
- Dec 2023
- Primary completion
- Apr 2024
- Modality
- Gene Editing, Gene Silencing, Small Molecules
01
Overview
A Phase 2 trial of ABX-101 in traumatic brain injury (TBI), sponsored by Abalonex, LLC. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
ABX-101
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT06096415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06096415.